Humanwell Healthcare Group Co Ltd
Humanwell Healthcare (Group) Co.,Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers sufentanil citrate injection, an analgesic drug for combined anesthesia; remifentanil hydrochloride injection for induction of general anesthesia and maintenance of analgesia during general anesthesia; hydromorphone hydrochloride injection for pa… Read more
Market Cap & Net Worth: Humanwell Healthcare Group Co Ltd (600079)
Humanwell Healthcare Group Co Ltd (SHG:600079) has a market capitalization of $4.25 Billion (CN¥31.19 Billion) as of March 18, 2026. Listed on the SHG stock exchange, this China-based company holds position #3484 globally and #287 in its home market, demonstrating a -2.45% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Humanwell Healthcare Group Co Ltd's stock price CN¥19.11 by its total outstanding shares 1632225965 (1.63 Billion).
Humanwell Healthcare Group Co Ltd Market Cap History: 2015 to 2026
Humanwell Healthcare Group Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $4.74 Billion to $4.25 Billion (0.67% CAGR).
Humanwell Healthcare Group Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Humanwell Healthcare Group Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.20x
Humanwell Healthcare Group Co Ltd's market cap is 0.20 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
3.91x
Humanwell Healthcare Group Co Ltd's market cap is 3.91 times its annual earnings
10.35x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $4.74 Billion | $10.05 Billion | $653.82 Million | 0.47x | 7.25x |
| 2016 | $4.27 Billion | $12.33 Billion | $832.40 Million | 0.35x | 5.13x |
| 2017 | $3.84 Billion | $15.45 Billion | $2.07 Billion | 0.25x | 1.86x |
| 2018 | $2.21 Billion | $18.63 Billion | -$2.36 Billion | 0.12x | N/A |
| 2019 | $2.95 Billion | $21.81 Billion | $842.54 Million | 0.14x | 3.50x |
| 2020 | $7.40 Billion | $20.37 Billion | $1.15 Billion | 0.36x | 6.44x |
| 2021 | $4.94 Billion | $20.44 Billion | $1.39 Billion | 0.24x | 3.55x |
| 2022 | $5.28 Billion | $22.34 Billion | $2.48 Billion | 0.24x | 2.13x |
| 2023 | $5.53 Billion | $24.52 Billion | $2.13 Billion | 0.23x | 2.59x |
| 2024 | $5.20 Billion | $25.44 Billion | $1.33 Billion | 0.20x | 3.91x |
Competitor Companies of 600079 by Market Capitalization
Companies near Humanwell Healthcare Group Co Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Humanwell Healthcare Group Co Ltd by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Humanwell Healthcare Group Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Humanwell Healthcare Group Co Ltd's market cap moved from $4.74 Billion to $ 4.25 Billion, with a yearly change of 0.67%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥4.25 Billion | +5.52% |
| 2025 | CN¥4.03 Billion | -22.54% |
| 2024 | CN¥5.20 Billion | -5.95% |
| 2023 | CN¥5.53 Billion | +4.71% |
| 2022 | CN¥5.28 Billion | +6.94% |
| 2021 | CN¥4.94 Billion | -33.25% |
| 2020 | CN¥7.40 Billion | +151.17% |
| 2019 | CN¥2.95 Billion | +33.23% |
| 2018 | CN¥2.21 Billion | -42.44% |
| 2017 | CN¥3.84 Billion | -10.06% |
| 2016 | CN¥4.27 Billion | -9.87% |
| 2015 | CN¥4.74 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Humanwell Healthcare Group Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.25 Billion USD |
| MoneyControl | $4.25 Billion USD |
| MarketWatch | $4.25 Billion USD |
| marketcap.company | $4.25 Billion USD |
| Reuters | $4.25 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.